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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. This study aimed to evaluate the relationship between gut probiotic
flora and nonalcoholic fatty liver disease in a diet induced rat
model, and to compare the effects of two different probiotic strains
on nonalcoholic fatty liver disease. Forty male Sprague Dawley rats
were randomized into 4 groups for 12 weeks: control (standard
rat chow), model (fat rich diet), Lactobacillus (fat rich diet plus
Lactobacillus acidophilus), and Bifidobacterium (fat rich diet plus
Bifidobacterium longum) groups. Probiotics were provided to rats
in drinking water (1010/ml). Gut bifidobacteria and lactobacilli were
obviously lower at weeks 8 and 10, respectively, in the model
group compared with the control group. Supplementation with
Bifidobacterium significantly attenuated hepatic fat accumulation
(0.10 ± 0.03 g/g liver tissue) compared with the model group
(0.16 ± 0.03 g/g liver tissue). However, there was no improvement
in intestinal permeability in either the Lactobacillus or the Bifido 
bacterium group compared with the model group. In all 40 rats,
the hepatic total lipid content was negatively correlated with gut
Lactobacillus (r = −0.623, p = 0.004) and Bifidobacterium (r = −0.591,
p = 0.008). Oral supplementation with probiotics attenuates hepatic
fat accumulation. Further, Bifidobacterium longum is superior in
terms of attenuating liver fat accumulation than is Lactobacillus
acidophilus.
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Introduction Hepatic steatosis or nonalcoholic fatty liver disease (NAFLD)
is an infiltration of fat inside hepatocytes, usually exceeding
5% of the liver wet weight.(1) NAFLD comprises a wide spectrum
of hepatic damage, from simple steatosis alone, to inflammatory
changes found in nonalcoholic steatohepatitis (NASH) and
advanced fibrosis and cirrhosis of the liver in the absence of
alcohol intake. The prevalence of NAFLD has apparently increased
in proportion to the increasing incidence of obesity in both adults
and children.(2,3) The “two-hit hypothesis” is currently widely
used to explain the development of NAFLD.(4) However, the
pathogenesis of NAFLD remains unclear. Closely associated
with obesity and insulin resistance, NAFLD is commoner in the
obese, diabetics, and patients with features of metabolic syndrome
than it is in normal healthy controls.(5,6)
The hypothesis that gut-derived bacteria and their products
could play a role in NAFLD is based on several studies. Wigg(7)
and Sabaté(8) found that the prevalence of small intestinal bacterial
overgrowth is higher in patients with NASH and morbid obesity
than it is in control subjects, and that it is associated with severe
hepatic steatosis. The association between bariatric surgery for
NASH and liver cirrhosis provided clinical evidence for the
hypothesis.(9,10) Furthermore, NAFLD and alcohol-induced liver
injury share similar pathogenic mechanisms. Rats administered
antibiotics and Lactobacillus are protected from ethanol-induced
liver damage,(11,12) which may be additional evidence for the hypo-
thesis. Intestinal bacteria may be involved in the mechanism of
NAFLD by means of an increased endogenous production of
ethanol, and direct activation of inflammatory cytokines in
luminal epithelial cells, non-parenchymal liver cells, or both via
release of lipopolysaccharide (LPS).(13)
Probiotics are inexpensive, safe, have no known long-term
adverse effects, and are widely accepted by the public. Supple-
mentation with probiotics for the management NAFLD would
seem to be an attractive idea. Li et al.(14) found that probiotic-
treated ob/ob mice had significantly decreased hepatic inflamma-
tion, serum alanine aminotransferase (ALT), and hepatic oleic acid
compared to the controls. A further animal study showed that oral
probiotic treatment significantly improved high-fat diet-induced
hepatic natural killer T cell depletion, insulin resistance, and
hepatic steatosis.(15) The beneficial effects of a probiotic VSL#3
(a mixture containing 450 billion bacteria of different strains)
were also observed in a small-scale human study.(16) Unfortunately,
all of the above studies failed to evaluate gut probiotic flora
longitudinally during the development of NAFLD. Therefore, the
aims of the present study were to evaluate gut probiotic flora
longitudinally and examine its association with liver fat accumula-
tion in a diet-induced rat model of NAFLD, and to compare the
effects of two different probiotic strains on NAFLD.
Materials and Methods
Animals and experimental protocol. Forty male Sprague-
Dawley rats (weighing 150–180 g), obtained from Shanghai Slac
Laboratory Animal LTD, were maintained on a 12-h light-dark
cycle at a constant room temperature of 20–22°C and humidity of
60–70%. After a 1-week adaptation, the rats were randomly
assigned to 4 groups (each group n = 10): control (C), model (M),
Lactobacillus (L), and Bifidobacterium (B). The rats in the groups
were maintained for 12 weeks with free access to food and water.
The control group received standard rat chow (M01-F; Shanghai
Slac Laboratory Animal Ltd.), the model group received a fat-rich
diet (weight ratio: standard rat chow, 60%; lard, 10%; sucrose,
9%; sesame oil, 1%; egg, 10%; milk powder, 5%; peanut, 5%),(17)
the  Lactobacillus group received the same fat-rich diet plus
Lactobacillus acidophilus (CGMCC 2106), and the Bifidobacterium
group received the fat-rich diet plus Bifidobacterium longum
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(CGMCC 2107). These two strains are common in human bowel
flora, the other one is they are acid resistance and were proved to
be effective in the treatment of human alcoholic cirrhosis.(14,18) The
probiotics were administered to rats in drinking water (1010/ml)
and prepared fresh each day.(19) Body weight was recorded once a
week. The animal study was approved by the Animal Ethics
Committee of Ren Ji Hospital, School of Medicine, Shanghai
Jiao Tong University.
Biochemical assays. Serum was separated from whole blood
and frozen at −80°C. Serum ALT, triglycerides (TG), and total
cholesterol (TC) were measured using an automatic biochemical
analytical system.
Liver histology and total lipids. Rats were anesthetized by
intraperitoneal sodium pentobarbital (60 mg/kg body weight) at
the end of the experimental period after overnight fasting. Livers
were rapidly excised and thin slices of liver were fixed in 10%
neutral-buffered formalin. Formalin-fixed, paraffin-embedded
liver sections were stained with H&E (hematoxylin and eosin) and
Sudan red IV. A further slice of liver tissue was quickly frozen in
liquid nitrogen and stored at −80°C for total lipid analysis. Total
lipids were extracted from liver tissue according to a published
method.(20)
Intestinal permeability. Intestinal permeability was deter-
mined at the end of the experiment using the method of Weaver
et al.(21) This procedure is based upon the differential absorption
of lactulose and mannitol; the greater the permeability, the higher
the ratio of lactulose to mannitol. After an overnight fast, each rat
received an intragastric permeability marker (2 ml) containing
100 mg lactulose (Wako Pure Chem., Osaka, Japan) and 50 mg
mannitol (Wako Pure Chem). Urine samples were collected for
24 h and stored at −80°C for analysis. The procedure used for
urine analysis was briefly as follows: Urine samples were boiled
and centrifuged at 1,000 rpm for 10 min. Five milliliters of the
resulting supernatant was transferred to a fresh microcentrifuge
tube. To this was added 10 μl acetic acid, followed by boiling for
5 min, and then, when cooled, centrifugation at 10,000 rpm for
10 min. Prior to analysis, the samples were initially filtered
through a 0.45-μm filter and then through a Microsep centrifugal
device (Pall Life Sciences, Washington DC) according to the
manufacturer’s instructions. The pretreated samples were analyzed
using a Dionex ICS 3000 ion chromatography system (Sunnyvale,
CA) as described previously.(22)
Gut probiotic flora. Fresh stool samples were collected every
2 weeks on Wednesday morning. One milliliter of PBS buffer
was added to each fecal specimen (180–220 mg), followed by
continuous vortexing for 5 min, and then centrifugation at 500 rpm
for 5 min. The resulting supernatant was transferred to a fresh
microcentrifuge tube, centrifuged at 14,000 × g for 5 min, and the
supernatant was discard. The bacterial pellets were used for
DNA extraction using a QIAamp DNA Stool Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. DNA
samples were stored at −80°C for PCR amplification.
The specific 16S rRNA-targeted primer sets used for quantita-
tive real-time PCR are listed in Table 1. The primer sets for Bifido-
bacterium and Lactobacillus were designed according to the
sequences obtained from public databases (www.ncbi.nlm.nih.gov)
and have been validated by other researchers.(23,24)
Each sample was measured in triplicate. Real-time PCR was
performed using the SYBR Green method. PCRs were performed
in 10-μl final volumes in a LightCycler 480 instrument (Roche
Diagnostic, Mannheim, Germany). Reaction mixtures contained
2× SYBR Premix Ex TaqTM (Takara Co., Kyoto, Japan), 5 μ1;
primer, 0.6 μl; DNA template, 1 μl; and ddH2O, 3.4 μl. Briefly,
after pre-denaturation of the DNA template at 95°C for 10 s, the
amplification program comprised 40 cycles (10 s at 95°C, 10 s at
60°C, and 60 s at 72°C for Bifidobacterium; and 10 s at 95°C, 10 s
at 56°C, and 60 s at 72°C for Lactobacillus). The temperature
transition rate was 20°C/s for all steps. The double-stranded PCR
products were measured during the 72°C extension step by detec-
tion of the fluorescence associated with the binding of SYBR
Green I to the products. No amplification was detected in the
negative control.
Melting curves were used to determine the specificity of the
PCR.(25) Melting curve analysis was performed immediately after
the amplification procedure under the following conditions: 95°C,
10 s (4.8°C/s); 65°C, 10 s (2.5°C/s); 95°C, 0 s (hold time, 0.21°C/s);
and 40°C, 1 s (2.5°C/s). Standard curves for Bifidobacterium
and  Lactobacillus were also generated in the LightCycler 480
instrument. Quantification of samples was achieved using the
standard curve prepared from a dilution series of known concen-
trations of plasmid DNA.
Statistical analysis. Data were analyzed using SPSS version
11.0 for Windows. Copy numbers of the 16S rRNA genes of
Bifidobacterium and Lactobacillus per gram of stool sample were
logarithmically transformed. Data are presented as the mean ± SD
for normally distributed data, and differences among the groups
were determined using a one-way ANOVA. If the data were non-
normally distributed, they are presented as the median plus range,
and were analyzed using a nonparametric test for K independent
samples. A two-sided p value of 0.05 was considered significant.
A Spearman linear correlation analysis was used to assess the
possible relationship among intestinal Bifidobacterium and
Lactobacillus and total hepatic lipids.
Results
Body weight. None of the rats died during the experiment.
The basal body weight of rats was comparable before the start of
the study. Body weight showed an obvious increase in the three
high-fat-fed groups compared with the control group from week 4
to the end of the study (all p<0.05). There was no significant
difference in body weight among the three high-fat-fed groups.
Serum ALT, TC, and TG. Serum ALT levels were similar
among the four groups (F = 0.876, p = 0.468). In contrast, serum
TC (F = 8.513, p = 0.001) and TG (F = 4.882, p = 0.011) were
markedly higher in the rats fed a fat-rich diet than in the control
rats. No significant differences were found among the three fat-
rich diet-fed groups with regard to TC and TG levels (Table 2).
Liver histology. Left panels were stained with H&E at
200× and right panels with Sudan red IV at 400× in Fig. 1. The
liver in the Control group showed no signs of lipid accumulation
with a normal structure of hepatic lobules (Fig. 1 A and B). Fat-
rich diet induced lipid accumulation mainly in the central vein area
of liver. The livers from the Model group showed microvesicular
Table 1. Specific primer sets used in the study
Target groups Primer Sequence (5' 3') PCR Products
Lactobacillus
L159 f GGA AAC AGA TGC TAA TAC CG
600 bp
L677 r CAC CGC TAC ACA TGG AG
Bifidobacterium
g Bifid f CTC CTG GAA ACG GGT GG
520 bp
g Bifid r GGT GTT CTT CCC GAT ATC TAC Adoi: 10.3164/jcbn.11 38
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and macrovesicular steatosis around the central vein area of liver.
The structure of hepatic lobule and cell cords were also destroyed
(Fig. 1 C and D). The livers showed mainly microvesicular
steatosis in the Lactobacillus group with a destroyed structure
of liver lobule (Fig. 1 E and F) while scattered microvesicular
steatosis in the Bifidobacterium group with a basically normal
hepatic lobule (Fig. 1 G and H).
Total lipid content and intestinal permeability. Hepatic 
lipid content was markedly higher in fat-rich diet-fed rats than in
the control rats. Although oral supplementation with Lactobacillus
failed to reduce hepatic lipid content (0.14 ± 0.02 g/g liver tissue)
compared with the model group (0.16 ± 0.03 g/g liver tissue),
that with Bifidobacterium significantly attenuated hepatic fat
accumulation (0.10 ± 0.03 g/g liver tissue) (Table 2). However,
there was no improvement in the intestinal permeability of either
the  Lactobacillus (median: 1.125, range: 0.920–1.344) or the
Bifidobacterium group (0.788, 0.492–2.164) compared with the
model group (0.774, 0.630–1.243) (Table 2).
Stool probiotic flora. Stool Bifidobacterium content at week
8 (Table 3) and Lactobacillus content at week 10 (Table 4) in the
model group were clearly lower than those in the control group,
and this phenomenon persisted until the end of the study (Fig. 2).
Oral supplementation with Bifidobacterium significantly increased
stool Bifidobacterium at week 2 compared with the model group.
Similarly, oral supplementation with Lactobacillus increased stool
Lactobacillus at week 12 (Fig. 2). In all 40 rats, hepatic total lipid
contents were positively correlated (r = 0.580,  p = 0.010) with
body weight, and negatively correlated with stool Lactobacillus
(r = −0.623,  p = 0.004) and stool Bifidobacterium ( r = −0.591,
p = 0.008).
Discussion
Not unexpectedly, the results of our study demonstrated that gut
probiotics are closely associated with NAFLD. Stool Bifido-
bacterium were obviously lower at week 8, and Lactobacillus
lower at week 10, in NAFLD model rats. Furthermore, in all 40
rats, hepatic total lipid contents were negatively correlated with
stool  Lactobacillus ( r = −0.623,  p = 0.004) and stool Bifido-
bacterium ( r = −0.591,  p = 0.008). These results are consistent
with those obtained in previous studies. Post-gastric bypass,
which is closely associated with NASH and liver cirrhosis,(9,10)
causes a large bacterial population shift.(26) Wigg et al.(7) assessed
small intestinal bacterial overgrowths in 22 patients with non-
alcoholic steatohepatitis and 23 control subjects using a combined
14C-D-xylose and lactulose breath test. Small intestinal bacterial
overgrowth was present in 50% of patients with nonalcoholic
steatosis and 22% of the control subjects. A further study,
conducted in 139 obese subjects, found that the prevalence of
small intestinal bacterial overgrowth was obviously higher in
obese subjects than in healthy controls (17.1% vs 2.5%). A multi-
variate regression showed that hepatic steatosis was associated
with small intestinal bacterial overgrowth,(8) and a human study by
Yao et al.(27) showed that presentation of gut microflora dysfunc-
tion was seen in 12 of 40 patients with fatty liver.
Increased intestinal permeability and gut-derived endotoxin are
considered to be important clues for the hypothesis of “liver and
lumen interaction”.(13) An increase in intestinal permeability,
reflected by the ratio of lactulose to mannitol, was also found in
NAFLD model rats compared with controls in our study. Interest-
ingly, however, we found that oral supplementation with probiotics
attenuated hepatic fat accumulation, although intestinal perme-
ability failed to improve. Accordingly, it would appear that
intestinal permeability does not play a role in the pathogenesis of
NAFLD. To date, we have not assessed whether there is an
increase in intestinal permeability in NAFLD subjects, as has been
suggested by recent studies. First, although the beneficial effects
of probiotic supplementation have been identified in both animal
and human studies, intestinal permeability has, unfortunately, not
been evaluated.(14,16,28) Second, in the studies in which intestinal
permeability was evaluated, the results were unclear. Wigg et al.(7)
were unable to demonstrate either an increase in small intestine
permeability (reflected by the lactulose-rhamnose sugar test) or
serum endotoxin level, whereas Jin et al.(29) found a progressive
increase of intestinal permeability (reflected by plasma D-lactate
and diamine oxidase levels) and endotoxin-induced intestinal
destruction in the development of nonalcoholic steatohepatitis.
Some plausible explanations for this paradox have been suggested,
including limitations of the limulus assay, binding of endotoxin to
plasma proteins, and the possibility that other bacterial products
such as peptidoglycan-polysaccharide polymers rather than
endotoxin could stimulate the release of TNF-α.(30) Another
possible explanation is that probiotic treatment plays a role by
reducing inflammatory signaling or inhibiting the production of
endogenous ethanol, which is thought to contribute to the patho-
genesis of NAFLD.(13–15)
Although there are numerous probiotics in nature, we still do
not know which are the most beneficial for humans. In studies on
probiotics, a mixture of probiotics is usually used,(14,16,28,31) and few
studies have compared the effects of single probiotics. Shima
et al.(32) found the Lactobacillus casei Shirota enhances intestinal
gene expression more strongly than Bifidobacterium breve Yakult.
Osmana et al.(33) compared the different effects of Lactobacillus
plantarum DSM 15313 and Bifidobacterium infantis DSM 15159
on endotoxin- and D-galactosamine-induced liver injury. DSM
15159 significantly decreased the release of ALT compared to the
DSM 15313 group, whereas short chain fatty acids (acetic acid
and propionic acid) were decreased significantly in the DSM
15313 group compared to the DSM 15159 group. In our study, we
found that oral supplementation with Bifidobacterium signifi-
cantly reversed the decrease in stool Bifidobacterium at week 2
compared with that in the model group, and that of Lactobacillus
at week 12. Bifidobacterium longum was superior in attenuating
liver fat accumulation, and there was a non-significant tendency
to decrease serum ALT and improve intestinal permeability
compared to Lactobacillus acidophilus (CGMCC 2106). There
were no significant differences between the two probiotic strains
in terms of body weight gain, serum TC, and serum TG. The
limitation of the study was that we didn’t detect the gene expres-
sion in the liver. Ten of genes are proved to be associated with the
Table 2. Serum ALT, TC, TG, hepatic lipids and intestinal permeability
Note: *p<0.05 vs other three groups respectively; +p<0.01 vs Model and Lactobacillus group; #abnormal distribution.
Groups ALT 
(IU/L)
TC 
(mmol/L)
TG 
(mmol/L)
Hepatic lipids 
(g/g liver tissue) L/M#
Control 58.9 ± 18.6 1.4 ± 0.1* 0.3 ± 0.1* 0.04 ± 0.01* 0.260 (0.082–0.329)*
Model 59.8 ± 6.8 1.7 ± 0.3 0.7 ± 0.1 0.16 ± 0.03 0.774 (0.630–1.243)
Lactobacillus 65.2 ± 8.1 1.6 ± 0.1 0.8 ± 0.3 0.14 ± 0.02 1.125 (0.920–1.344)
Bifidobacterium 52.3 ± 11.3 1.8 ± 0.2 0.7 ± 0.1 0.10 ± 0.03+ 0.788 (0.492–2.164) J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 75
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Fig. 1. Effect of probiotics on rat hepatic histology. (Left panels H&E staining at 200× and right panels Sudan red IV staining at 400×). (A, B)
Control; (C, D) Model; (E, F) fat rich diet plus Lactobacillus acidophilus; (G, H) fat rich diet plus Bifidobacterium longum.doi: 10.3164/jcbn.11 38
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development of NAFLD and we didn’t know which gene play a
key role in the NAFLD. A gene chip may be used to reveal the
relationship between the gut flora and the liver.
In conclusion, hepatic total lipid content is closely associated
with gut probiotic flora. Oral supplementation with probiotics
attenuates hepatic fat accumulation without improving body
weight and intestinal permeability. Bifidobacterium longum has a
superior ability to attenuate liver fat accumulation compared to
Lactobacillus acidophilus.
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Abbreviations
ALT alanine aminotransferase
B Bifidobacterium
C control
L Lactobacillus
LPS lipopolysaccharide
M model
NAFLD nonalcoholic fatty liver disease
TC total cholesterol
TG triglycerides
Table 3. The concentration of stool lactobacillus in the study (Log copy/ml)
Note: The difference among the groups was made by one way ANOVA. *p<0.001 vs model group.
Group 
Time Control Model Lactobacillus Bifidobacterium F value p value
2w 11.8 ± 0.8 11.4 ± 0.6 11.1 ± 0.5 11.6 ± 0.5 1.123 0.361
4w 12.4 ± 0.2 12.2 ± 0.4 11.9 ± 0.2 12.3 ± 0.2 2.004 0.140
6w 12.6 ± 0.5 12.4 ± 0.3 12.7 ± 0.2 12.0 ± 0.7 2.514 0.088
8w 12.7 ± 0.2 12.6 ± 0.6 12.5 ± 0.5 12.5 ± 0.3 0.594 0.626
10w 12.8 ± 0.5 11.8 ± 0.5 12.2 ± 0.4 13.0 ± 0.3 6.799 0.004
12w 11.9 ± 0.5 10.4 ± 0.6 12.1 ± 0.1* 12.8 ± 0.3 25.814 0.000
Table 4. The concentration of stool bifidobacterium in the study (Log copy/ml)
Note: The difference among the groups was made by one way ANOVA. *p<0.05 vs model group.
Group 
Time Control Model Lactobacillus Bifidobacterium F value p value
2w 11.0 ± 0.9 10.8 ± 0.9 11.9 ± 0.5 11.5 ± 0.9 1.782 0.181
4w 10.3 ± 0.6 10.6 ± 0.7 10.7 ± 0.8 11.8 ± 0.3* 7.543 0.001
6w 10.0 ± 0.4 10.2 ± 0.4 10.1 ± 0.7 11.2 ± 0.8* 5.180 0.008
8w 10.2 ± 0.3 9.7 ± 0.3 10.3 ± 0.2 10.4 ± 0.3* 6.872 0.002
10w 10.3 ± 0.5 9.6 ± 0.4 10.3 ± 0.6 10.5 ± 0.1* 6.748 0.004
12w 10.5 ± 0.4 9.5 ± 0.3 10.4 ± 0.9 10.7 ± 0.4* 7.793 0.002
Fig. 2. Trends of Lactobacillus (A) and Bifidobacterium (B) in the study. Data were shown as mean ± SD. Note: C: control; M: model group; L: Lacto 
bacillus group; B: Bifidobacterium group. The difference among the groups was made by one way ANOVA. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 77
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